β-Glucan reprograms neutrophils to promote disease tolerance against influenza A virus

Disease tolerance is an evolutionarily conserved host defense strategy that preserves tissue integrity and physiology without affecting pathogen load. Unlike host resistance, the mechanisms underlying disease tolerance remain poorly understood. In the present study, we investigated whether an adjuvant (β-glucan) can reprogram innate immunity to provide protection against influenza A virus (IAV) infection. β-Glucan treatment reduces the morbidity and mortality against IAV infection, independent of host resistance. The enhanced survival is the result of increased recruitment of neutrophils via RoRγt+ T cells in the lung tissue. β-Glucan treatment promotes granulopoiesis in a type 1 interferon-dependent manner…

• BA
  Bill and Melinda Gates Foundation

  Award: INV-003360
• MU
  McGill University
• MU
  McGill University Health Centre
• RS
  Royal Society of Canada
• RS
  Royal Society
• DF
  Deutsche Forschungsgemeinschaft

  Awards: 502158695, CRC TRR332, TRR332
• WW
  Westfälische Wilhelms-Universität Münster
• NI
  National Institutes of Health

  Award: NIH-U01
• CI
  Canadian Institutes of Health Research

  Award: 168885
• NI
  National Institute of Allergy and Infectious Diseases

  Award: AI160406